QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
☐ | TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ |
(State or other jurisdiction of incorporation or organization) | (IRS Employer Identification No.) | |||
(Address of principal executive offices) | (Zip code) | |||
Title of each class | Trading symbol(s) | Name of Exchange on Which Registered |
☒ | Accelerated Filer | ☐ | ||
Non-Accelerated Filer | ☐ | Smaller Reporting Company | ||
Emerging Growth Company | ||||
Page | ||
ITEM 1. | FINANCIAL STATEMENTS |
June 30, 2020 | March 31, 2020 | |||||||
(Unaudited) | ||||||||
Assets | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | $ | ||||||
Accounts receivable (net of allowances of $10,839 and $12,051 respectively) | ||||||||
Inventories, net | ||||||||
Prepaid expenses and other current assets | ||||||||
Total current assets | ||||||||
Property, plant, and equipment, net | ||||||||
Lease right-of-use assets, net | ||||||||
Goodwill | ||||||||
Intangibles, net | ||||||||
Other assets | ||||||||
Total assets | $ | $ | ||||||
Liabilities and equity | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | $ | ||||||
Accrued income taxes | ||||||||
Accrued payroll and other related liabilities | ||||||||
Short-term indebtedness | ||||||||
Lease obligations due within one year | ||||||||
Accrued expenses and other | ||||||||
Total current liabilities | ||||||||
Long-term indebtedness | ||||||||
Deferred income taxes, net | ||||||||
Long-term lease obligations | ||||||||
Other liabilities | ||||||||
Total liabilities | $ | $ | ||||||
Commitments and contingencies (see Note 8) | ||||||||
Ordinary shares, with $.001 par value; 500,000 shares authorized; 85,060 and 84,924 ordinary shares issued and outstanding, respectively | ||||||||
Retained earnings | ||||||||
Accumulated other comprehensive (loss) | ( | ) | ( | ) | ||||
Total shareholders’ equity | ||||||||
Noncontrolling interests | ||||||||
Total equity | ||||||||
Total liabilities and equity | $ | $ | ||||||
Three Months Ended June 30, | ||||||||
2020 | 2019 | |||||||
Revenues: | ||||||||
Product | $ | $ | ||||||
Service | ||||||||
Total revenues | ||||||||
Cost of revenues: | ||||||||
Product | ||||||||
Service | ||||||||
Total cost of revenues | ||||||||
Gross profit | ||||||||
Operating expenses: | ||||||||
Selling, general, and administrative | ||||||||
Research and development | ||||||||
Restructuring expenses | ||||||||
Total operating expenses | ||||||||
Income from operations | ||||||||
Non-operating expenses, net: | ||||||||
Interest expense | ||||||||
Interest (income) and miscellaneous expense | ( | ) | ||||||
Total non-operating expenses, net | ||||||||
Income before income tax expense | ||||||||
Income tax expense | ||||||||
Net income | ||||||||
Less: Net (loss) income attributable to noncontrolling interests | ( | ) | ||||||
Net income attributable to shareholders | $ | $ | ||||||
Net income per share attributed to shareholders | ||||||||
Basic | $ | $ | ||||||
Diluted | $ | $ | ||||||
Cash dividends declared per share ordinary outstanding | $ | $ | ||||||
Three Months Ended June 30, | ||||||||
2020 | 2019 | |||||||
Net income | $ | $ | ||||||
Less: Net (loss) income attributable to noncontrolling interests | ( | ) | ||||||
Net income attributable to shareholders | ||||||||
Other comprehensive income (loss) | ||||||||
Amortization of pension and postretirement benefit plans cost, (net of taxes of $174 and $170, respectively) | ( | ) | ( | ) | ||||
Change in cumulative currency translation adjustment | ||||||||
Total other comprehensive income | ||||||||
Comprehensive income | $ | $ | ||||||
Three Months Ended June 30, | ||||||||
2020 | 2019 | |||||||
Operating activities: | ||||||||
Net income | $ | $ | ||||||
Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||
Depreciation, depletion, and amortization | ||||||||
Deferred income taxes | ( | ) | ( | ) | ||||
Share-based compensation expense | ||||||||
Loss on the disposal of property, plant, equipment, and intangibles, net | ||||||||
Loss on sale of businesses, net | ||||||||
Other items | ||||||||
Changes in operating assets and liabilities, net of effects of acquisitions: | ||||||||
Accounts receivable, net | ||||||||
Inventories, net | ( | ) | ( | ) | ||||
Other current assets | ( | ) | ( | ) | ||||
Accounts payable | ( | ) | ( | ) | ||||
Accruals and other, net | ( | ) | ( | ) | ||||
Net cash provided by operating activities | ||||||||
Investing activities: | ||||||||
Purchases of property, plant, equipment, and intangibles, net | ( | ) | ( | ) | ||||
Proceeds from the sale of property, plant, and equipment | ||||||||
Proceeds from the sale of businesses | ||||||||
Acquisition of businesses, net of cash acquired | ( | ) | ||||||
Net cash used in investing activities | ( | ) | ( | ) | ||||
Financing activities: | ||||||||
Proceeds (payments) under credit facilities, net | ( | ) | ||||||
Deferred financing fees and debt issuance costs | ( | ) | ||||||
Acquisition related deferred or contingent consideration | ( | ) | ( | ) | ||||
Repurchases of ordinary shares | ( | ) | ( | ) | ||||
Cash dividends paid to ordinary shareholders | ( | ) | ( | ) | ||||
Contributions from non-controlling interest | ||||||||
Stock option and other equity transactions, net | ||||||||
Net cash used in financing activities | ( | ) | ( | ) | ||||
Effect of exchange rate changes on cash and cash equivalents | ||||||||
Increase in cash and cash equivalents | ( | ) | ||||||
Cash and cash equivalents at beginning of period | ||||||||
Cash and cash equivalents at end of period | $ | $ | ||||||
Ordinary Shares | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Non-controlling Interest | Total Equity | |||||||||||||
Number | Amount | ||||||||||||||||
Balance at March 31, 2020 | $ | $ | ( | ) | $ | $ | |||||||||||
Comprehensive income: | |||||||||||||||||
Net income (loss) | — | ( | ) | ||||||||||||||
Other comprehensive income | — | — | — | — | |||||||||||||
Repurchases of ordinary shares | ( | ) | ( | ) | ( | ) | — | ( | ) | ||||||||
Equity compensation programs and other | |||||||||||||||||
Cash dividends – $0.37 per ordinary share | — | ( | ) | ( | ) | ||||||||||||
Contributions from non-controlling interest | — | — | — | — | |||||||||||||
Other changes in noncontrolling interest | — | ||||||||||||||||
Balance at June 30, 2020 | $ | $ | $ | ( | ) | $ | $ | ||||||||||
Ordinary Shares | Retained Earnings | Accumulated Other Comprehensive Income (Loss) | Non-controlling Interest | Total Equity | |||||||||||||
Number | Amount | ||||||||||||||||
Balance at March 31, 2019 | $ | $ | ( | ) | $ | $ | |||||||||||
Comprehensive income: | |||||||||||||||||
Net income | — | ||||||||||||||||
Other comprehensive income | — | — | — | — | |||||||||||||
Repurchases of ordinary shares | ( | ) | ( | ) | — | ( | ) | ||||||||||
Equity compensation programs and other | |||||||||||||||||
Cash dividends – $0.34 per ordinary share | — | ( | ) | ( | ) | ||||||||||||
Other changes in noncontrolling interest | — | ( | ) | ( | ) | ||||||||||||
Balance at June 30, 2019 | $ | $ | $ | ( | ) | $ | $ | ||||||||||
Standard | Date of Issuance | Description | Date of Adoption | Effect on the financial statements or other significant matters | ||||
Standards that have been adopted in fiscal 2021 | ||||||||
ASU 2016-13, "Measurement of Credit Losses on Financial Instruments" | June 2016 | The standard required a financial asset (or group of financial assets) measured at amortized cost to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. Credit losses relating to available-for-sale debt securities should be recorded through an allowance for credit losses. The standard was effective for annual periods beginning after December 15, 2019. | First Quarter Fiscal 2021 | We adopted this standard effective April 1, 2020 with no material impact to our consolidated financial statements. | ||||
ASU 2018-13 "Fair Value Measurement (Topic 820) Disclosure Framework- Changes to Disclosure Requirements for Fair Value Measurement” | August 2018 | The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for fair value measurements for assets and liabilities disclosed within the fair value hierarchy. The standard was effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2019. | First Quarter Fiscal 2021 | We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only. | ||||
ASU 2018-14 "Compensation- Retirement Benefits - Defined Benefit Plans- General Topic (715-20): Disclosure Framework- Changes to the Disclosure Requirements for Defined Benefit Plans" | August 2018 | The standard modified the disclosure requirements by adding, removing, and modifying certain required disclosures for employers that sponsor defined benefit pension or other post-retirement benefit plans. The standard also clarified disclosure requirements for defined benefit pension plans relating to the projected benefit obligation and accumulated benefit obligation. The standard was effective for fiscal years ending after December 15, 2019. | First Quarter Fiscal 2021 | We adopted this standard effective April 1, 2020 with no material impact on our consolidated financial statements as it modifies disclosure requirements only. | ||||
ASU 2018-15 "Intangibles- Goodwill and Other- Internal Use Software (Subtopic 350-40): Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement that is a Service Contract" | August 2018 | The standard aligned the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The standard was effective for fiscal years beginning after December 15, 2019. | First Quarter Fiscal 2021 | We adopted this standard on April 1, 2020 using the prospective method. The adoption of this standard did not have a material impact on our consolidated financial statements and disclosures. | ||||
Standards that have not yet been adopted | ||||||||
ASU 2019-12 "Income Taxes (Topic 740)" | December 2019 | The standard provides final guidance that simplifies the accounting for income taxes by eliminating certain exceptions to the guidance in ASC 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The guidance simplifies accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. The standard is effective for fiscal years beginning after December 15, 2020 and early adoption is permitted. | N/A | We are in the process of evaluating the impact that the standard will have on our consolidated financial statements. | ||||
June 30, 2020 | March 31, 2020 | |||||||
Raw materials | $ | $ | ||||||
Work in process | ||||||||
Finished goods | ||||||||
LIFO reserve | ( | ) | ( | ) | ||||
Reserve for excess and obsolete inventory | ( | ) | ( | ) | ||||
Inventories, net | $ | $ | ||||||
June 30, 2020 | March 31, 2020 | |||||||
Land and land improvements (1) | $ | $ | ||||||
Buildings and leasehold improvements | ||||||||
Machinery and equipment | ||||||||
Information systems | ||||||||
Radioisotope | ||||||||
Construction in progress (1) | ||||||||
Total property, plant, and equipment | ||||||||
Less: accumulated depreciation and depletion | ( | ) | ( | ) | ||||
Property, plant, and equipment, net | $ | $ | ||||||
(1) | Land is not depreciated. Construction in progress is not depreciated until placed in service. |
June 30, 2020 | March 31, 2020 | |||||||
Short term debt | ||||||||
Private Placement | $ | $ | ||||||
Total short term debt | $ | $ | ||||||
Long term debt | ||||||||
Credit Agreement | $ | $ | ||||||
Private Placement | ||||||||
Deferred financing costs | ( | ) | ( | ) | ||||
Total long term debt | $ | $ | ||||||
Total debt | $ | $ | ||||||
June 30, 2020 | March 31, 2020 | |||||||
Accrued payroll and other related liabilities: | ||||||||
Compensation and related items | $ | $ | ||||||
Accrued vacation/paid time off | ||||||||
Accrued bonuses | ||||||||
Accrued employee commissions | ||||||||
Other postretirement benefit obligations-current portion | ||||||||
Other employee benefit plans obligations-current portion | ||||||||
Total accrued payroll and other related liabilities | $ | $ | ||||||
Accrued expenses and other: | ||||||||
Deferred revenues | $ | $ | ||||||
Service liabilities | ||||||||
Self-insured risk reserves-current portion | ||||||||
Accrued dealer commissions | ||||||||
Accrued warranty | ||||||||
Asset retirement obligation-current portion | ||||||||
Other | ||||||||
Total accrued expenses and other | $ | $ | ||||||
Other liabilities: | ||||||||
Self-insured risk reserves-long-term portion | $ | $ | ||||||
Other postretirement benefit obligations-long-term portion | ||||||||
Defined benefit pension plans obligations-long-term portion | ||||||||
Other employee benefit plans obligations-long-term portion | ||||||||
Accrued long-term income taxes | ||||||||
Asset retirement obligation-long-term portion | ||||||||
Other | ||||||||
Total other liabilities | $ | $ | ||||||
Three Months Ended June 30, | ||||||||
2020 | 2019 | |||||||
Revenues: | ||||||||
Healthcare | $ | $ | ||||||
Applied Sterilization Technologies | ||||||||
Life Sciences | ||||||||
Total revenues | $ | $ | ||||||
Operating income (loss): | ||||||||
Healthcare | $ | $ | ||||||
Applied Sterilization Technologies | ||||||||
Life Sciences | ||||||||
Corporate | ( | ) | ( | ) | ||||
Total operating income before adjustments | $ | $ | ||||||
Less: Adjustments | ||||||||
Amortization of acquired intangible assets (1) | $ | $ | ||||||
Acquisition and integration related charges (2) | ||||||||
Redomiciliation and tax restructuring costs (3) | ||||||||
Net loss on divestiture of businesses (1) | ||||||||
Amortization of property "step up" to fair value (1) | ||||||||
COVID-19 incremental costs (4) | ||||||||
Restructuring charges (5) | ||||||||
Total operating income | $ | $ | ||||||
Three Months Ended June 30, | ||||||||
2020 | 2019 | |||||||
Healthcare: | ||||||||
Consumables | $ | $ | ||||||
Capital equipment | ||||||||
Service | ||||||||
Total Healthcare Revenues | $ | $ | ||||||
Applied Sterilization Technologies Service Revenues | $ | $ | ||||||
Life Sciences: | ||||||||
Consumables | $ | $ | ||||||
Capital equipment | ||||||||
Service | ||||||||
Total Life Sciences Revenues | $ | $ | ||||||
Total Revenues | $ | $ | ||||||
Three Months Ended June 30, | ||||||||
2020 | 2019 | |||||||
Revenues: | ||||||||
Ireland | $ | $ | ||||||
United States | ||||||||
Other locations | ||||||||
Total Revenues | $ | $ | ||||||
June 30, 2020 | March 31, 2020 | |||||||
Assets: | ||||||||
Healthcare and Life Sciences | $ | $ | ||||||
Applied Sterilization Technologies | ||||||||
Total assets | $ | $ | ||||||
Three Months Ended June 30, | ||||||
Denominator (shares in thousands): | 2020 | 2019 | ||||
Weighted average shares outstanding—basic | ||||||
Dilutive effect of share equivalents | ||||||
Weighted average shares outstanding and share equivalents—diluted | ||||||
Three Months Ended June 30, | ||||||
(shares in thousands) | 2020 | 2019 | ||||
Number of share options | ||||||
Fiscal 2021 | Fiscal 2020 | |||||
Risk-free interest rate | % | % | ||||
Expected life of options | ||||||
Expected dividend yield of stock | % | % | ||||
Expected volatility of stock | % | % | ||||
Number of Options | Weighted Average Exercise Price | Average Remaining Contractual Term | Aggregate Intrinsic Value | ||||||||||
Outstanding at March 31, 2020 | $ | ||||||||||||
Granted | |||||||||||||
Exercised | ( | ) | |||||||||||
Forfeited | ( | ) | |||||||||||
Outstanding at June 30, 2020 | $ | $ | |||||||||||
Exercisable at June 30, 2020 | $ | $ | |||||||||||
Number of Restricted Shares | Number of Restricted Share Units | Weighted-Average Grant Date Fair Value | ||||||||
Non-vested at March 31, 2020 | $ | |||||||||
Granted | ||||||||||
Vested | ( | ) | ( | ) | ||||||
Forfeited | ( | ) | ||||||||
Non-vested at June 30, 2020 | $ | |||||||||
Warranties | |||
Balance, March 31, 2020 | $ | ||
Warranties issued during the period | |||
Settlements made during the period | ( | ) | |
Balance, June 30, 2020 | $ | ||
Asset Derivatives | Liability Derivatives | |||||||||||||||
Fair Value at | Fair Value at | Fair Value at | Fair Value at | |||||||||||||
Balance sheet location | June 30, 2020 | March 31, 2020 | June 30, 2020 | March 31, 2020 | ||||||||||||
Prepaid & Other | $ | $ | $ | $ | ||||||||||||
Accrued expenses and other | $ | $ | $ | $ | ||||||||||||
Location of gain (loss) recognized in income | Amount of gain (loss) recognized in income | |||||||||
Three Months Ended June 30, | ||||||||||
2020 | 2019 | |||||||||
Foreign currency forward contracts | Selling, general and administrative | $ | $ | |||||||
Commodity swap contracts | Cost of revenues | $ | $ | ( | ) | |||||
Fair Value Measurements | ||||||||||||||||||||||||||||||
Carrying Value | Quoted Prices in Active Markets for Identical Assets | Significant Other Observable Inputs | Significant Unobservable Inputs | |||||||||||||||||||||||||||
Level 1 | Level 2 | Level 3 | ||||||||||||||||||||||||||||
June 30, | March 31, | June 30, | March 31, | June 30, | March 31, | June 30, | March 31, | |||||||||||||||||||||||
Assets: | ||||||||||||||||||||||||||||||
Cash and cash equivalents | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||
Forward and swap contracts (1) | ||||||||||||||||||||||||||||||
Equity investments(2) | — | — | — | — | — | |||||||||||||||||||||||||
Other investments | — | |||||||||||||||||||||||||||||
Liabilities: | ||||||||||||||||||||||||||||||
Forward and swap contracts (1) | $ | $ | $ | $ | $ | $ | $ | $ | ||||||||||||||||||||||
Deferred compensation plans (2) | ||||||||||||||||||||||||||||||
Total debt (3) | ||||||||||||||||||||||||||||||
Contingent consideration obligations (4) | ||||||||||||||||||||||||||||||
Contingent Consideration | ||||
Balance at March 31, 2020 | $ | |||
Additions | ||||
Payments | ( | ) | ||
Currency translation adjustments | ( | ) | ||
Balance at June 30, 2020 | $ | |||
Defined Benefit Plans (1) | Currency Translation (2) | Total Accumulated Other Comprehensive Income (Loss) | |||||||||
Balance at March 31, 2020 | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||
Other Comprehensive (Loss) Income before reclassifications | |||||||||||
Amounts reclassified from Accumulated Other Comprehensive (Loss) Income | ( | ) | ( | ) | |||||||
Net current-period Other Comprehensive (Loss) Income | ( | ) | |||||||||
Balance at June 30, 2020 | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||
Defined Benefit Plans (1) | Currency Translation (2) | Total Accumulated Other Comprehensive Income (Loss) | ||||||||
Balance at March 31, 2019 | $ | ( | ) | $ | ( | ) | $ | ( | ) | |
Other Comprehensive Income (Loss) before reclassifications | ||||||||||
Amounts reclassified from Accumulated Other Comprehensive (Loss) | ( | ) | ( | ) | ||||||
Net current-period Other Comprehensive (Loss) | ( | ) | ||||||||
Balance at June 30, 2019 | $ | ( | ) | $ | ( | ) | $ | ( | ) | |
ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
• | what factors affect our business; |
• | what our earnings and costs were in each period presented; |
• | why those earnings and costs were different from prior periods; |
• | where our earnings came from; |
• | how this affects our overall financial condition; |
• | what our expenditures for capital projects were; and |
• | where cash will come from to fund future debt principal repayments, growth outside of core operations, repurchases of shares, pay cash dividends and fund future working capital needs. |
• | Backlog – We define backlog as the amount of unfilled capital equipment purchase orders at a point in time. We use this figure as a measure to assist in the projection of short-term financial results and inventory requirements. |
• | Debt-to-total capital – We define debt-to-total capital as total debt divided by the sum of total debt and shareholders’ equity. We use this figure as a financial liquidity measure to gauge our ability to borrow and fund growth. |
• | Days sales outstanding (“DSO”) – We define DSO as the average collection period for accounts receivable. It is calculated as net accounts receivable divided by the trailing four quarters’ revenues, multiplied by 365 days. We use this figure to help gauge the quality of accounts receivable and expected time to collect. |
• | Revenues – Our revenues are presented net of sales returns and allowances. |
• | Product Revenues – We define product revenues as revenues generated from sales of consumable and capital equipment products. |
• | Service Revenues – We define service revenues as revenues generated from parts and labor associated with the maintenance, repair, and installation of our capital equipment. Service revenues also include hospital sterilization services, instrument and scope repairs, as well as revenues generated from contract sterilization and laboratory services offered through our Applied Sterilization Technologies segment. |
• | Capital Equipment Revenues – We define capital equipment revenues as revenues generated from sales of capital equipment, which includes: steam and gas sterilizers, low temperature liquid chemical sterilant processing systems, pure steam/water systems, surgical lights and tables, and integrated OR. |
• | Consumable Revenues – We define consumable revenues as revenues generated from sales of the consumable family of products, which includes dedicated consumables including V-PRO, SYSTEM 1 and 1E consumables, gastrointestinal endoscopy accessories, sterility assurance products, barrier protection solutions, cleaning consumables, and surgical instruments. |
• | Recurring Revenues – We define recurring revenues as revenues generated from sales of consumable products and service revenues. |
Three Months Ended June 30, | ||||||||
(dollars in thousands) | 2020 | 2019 | ||||||
Net cash provided by operating activities | $ | 134,122 | $ | 109,337 | ||||
Purchases of property, plant, equipment and intangibles, net | (66,861 | ) | (49,794 | ) | ||||
Proceeds from the sale of property, plant, equipment and intangibles | 137 | 18 | ||||||
Free cash flow | $ | 67,398 | $ | 59,561 | ||||
Three Months Ended June 30, | |||||||||||||||
(dollars in thousands) | 2020 | 2019 | Change | Percent Change | |||||||||||
Total revenues | $ | 668,932 | $ | 696,803 | $ | (27,871 | ) | (4.0 | )% | ||||||
Revenues by type: | |||||||||||||||
Service revenues | 367,824 | 389,068 | (21,244 | ) | (5.5 | )% | |||||||||
Consumable revenues | 142,596 | 160,111 | (17,515 | ) | (10.9 | )% | |||||||||
Capital equipment revenues | 158,512 | 147,624 | 10,888 | 7.4 | % | ||||||||||
Revenues by geography: | |||||||||||||||
Ireland revenues | 14,373 | 15,108 | (735 | ) | (4.9 | )% | |||||||||
United States revenues | 491,708 | 511,152 | (19,444 | ) | (3.8 | )% | |||||||||
Other foreign revenues | 162,851 | 170,543 | (7,692 | ) | (4.5 | )% | |||||||||
Three Months Ended June 30, | Change | Percent Change | |||||||||||||
(dollars in thousands) | 2020 | 2019 | |||||||||||||
Gross profit: | |||||||||||||||
Product | $ | 144,553 | $ | 146,776 | $ | (2,223 | ) | (1.5 | )% | ||||||
Service | 141,015 | 159,067 | (18,052 | ) | (11.3 | )% | |||||||||
Total gross profit | $ | 285,568 | $ | 305,843 | $ | (20,275 | ) | (6.6 | )% | ||||||
Gross profit percentage: | |||||||||||||||
Product | 48.0 | % | 47.7 | % | |||||||||||
Service | 38.3 | % | 40.9 | % | |||||||||||
Total gross profit percentage | 42.7 | % | 43.9 | % | |||||||||||
Three Months Ended June 30, | Change | Percent Change | |||||||||||||
(dollars in thousands) | 2020 | 2019 | |||||||||||||
Operating expenses: | |||||||||||||||
Selling, general, and administrative | $ | 155,170 | $ | 178,781 | $ | (23,611 | ) | (13.2 | )% | ||||||
Research and development | 16,231 | 15,585 | 646 | 4.1 | % | ||||||||||
Restructuring expenses | 166 | 1,389 | (1,223 | ) | NM | ||||||||||
Total operating expenses | $ | 171,567 | $ | 195,755 | $ | (24,188 | ) | (12.4 | )% | ||||||
Three Months Ended June 30, | ||||||||||||
(dollars in thousands) | 2020 | 2019 | Change | |||||||||
Non-operating expenses, net: | ||||||||||||
Interest expense | $ | 9,492 | $ | 10,445 | $ | (953 | ) | |||||
Interest (income) and miscellaneous expense | (2,289 | ) | 233 | (2,522 | ) | |||||||
Non-operating expenses, net | $ | 7,203 | $ | 10,678 | $ | (3,475 | ) | |||||
Three Months Ended June 30, | Change | Percent Change | ||||||||||||
(dollars in thousands) | 2020 | 2019 | ||||||||||||
Income tax expense | $ | 18,674 | $ | 14,633 | $ | 4,041 | 27.6% | |||||||
Effective income tax rate | 17.5 | % | 14.7 | % | ||||||||||
Three Months Ended June 30, | ||||||||
(dollars in thousands) | 2020 | 2019 | ||||||
Revenues: | ||||||||
Healthcare | $ | 399,658 | $ | 445,732 | ||||
Applied Sterilization Technologies | 152,362 | 154,286 | ||||||
Life Sciences | 116,912 | 96,785 | ||||||
Total revenues | $ | 668,932 | $ | 696,803 | ||||
Operating income (loss): | ||||||||
Healthcare | $ | 82,357 | $ | 90,515 | ||||
Applied Sterilization Technologies | 63,955 | 68,035 | ||||||
Life Sciences | 48,461 | 33,039 | ||||||
Corporate | (52,367 | ) | (55,397 | ) | ||||
Total operating income before adjustments | $ | 142,406 | $ | 136,192 | ||||
Less: Adjustments | ||||||||
Amortization of acquired intangible assets (1) | $ | 17,500 | $ | 16,949 | ||||
Acquisition and integration related charges (2) | 1,286 | 1,917 | ||||||
Redomiciliation and tax restructuring costs (3) | 170 | 1,770 | ||||||
Net loss on divestiture of businesses (1) | 10 | 2,426 | ||||||
Amortization of property "step up" to fair value (1) | 603 | 735 | ||||||
COVID-19 incremental costs (4) | 8,670 | — | ||||||
Restructuring charges (5) | 166 | 2,307 | ||||||
Total operating income | $ | 114,001 | $ | 110,088 | ||||
Three Months Ended June 30, | ||||||||
(dollars in thousands) | 2020 | 2019 | ||||||
Net cash provided by operating activities | $ | 134,122 | $ | 109,337 | ||||
Net cash (used in) investing activities | $ | (66,724 | ) | $ | (84,307 | ) | ||
Net cash (used in) provided by financing activities | $ | (134,000 | ) | $ | (7,607 | ) | ||
Debt-to-total capital ratio | 23.3 | % | 27.2 | % | ||||
Free cash flow | $ | 67,398 | $ | 59,561 | ||||
• | Purchases of property, plant, equipment, and intangibles, net – Capital expenditures were $66.9 million for the first three months of fiscal 2021 and $49.8 million during the same prior year period. The increase was primarily due to expansion projects in the Applied Sterilization Technologies segment. |
• | Acquisitions of businesses, net of cash acquired – During the first three months of fiscal 2020, we used $35.0 million million for the purchase of businesses. For more information on our acquisitions, refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. |
• | Proceeds (payments) under credit facility, net – Net payments under credit facilities totaled $95.8 million in the first three months of fiscal 2021, compared to net proceeds under credit facilities of $27.9 million in the first three months of fiscal 2020. |
• | Repurchases of ordinary shares – During the first three months of fiscal 2021 through April 9, 2020, we purchased 35,000 of our ordinary shares in the aggregate amount of $5.0 million. During the first three months of fiscal 2021, we obtained 63,150 of our ordinary shares in connection with share-based compensation award programs in the aggregate amount of $9.2 million. During the first three months of fiscal 2020, we purchased 52,000 of our ordinary shares in the aggregate amount of $7.5 million. During the first three months of fiscal 2020, we obtained 66,745 of our ordinary shares in connection with share-based compensation award programs in the aggregate amount of $7.4 million. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020. |
• | Cash dividends paid to ordinary shareholders – During the first three months of fiscal 2021, we paid total cash dividends of $31.5 million, or $0.37 per outstanding share. During the first three months of fiscal 2020, we paid total cash dividends of $28.8 million, or $0.34 per outstanding share. |
• | Contributions from noncontrolling interest – During the first three months of fiscal 2021, we received contributions from noncontrolling interest holders of $2.3 million. |
• | Stock option and other equity transactions, net – We generally receive cash for issuing shares under our stock option programs. During the first three months of fiscal 2021 and fiscal 2020, we received cash proceeds totaling $5.4 million and $9.9 million, respectively, under these programs. |
ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
ITEM 4. | CONTROLS AND PROCEDURES |
ITEM 1. | LEGAL PROCEEDINGS |
ITEM 1A. | RISK FACTORS |
(a) Total Number of Shares Purchased | (b) Average Price Paid Per Share | (c) Total Number of Shares Purchased as Part of Publicly Announced Plans | (d) Maximum Dollar Value of Shares that May Yet Be Purchased Under the Plans at Period End (in thousands) | ||||||||||||
April 1-30 | 35,000 | $ | 144.21 | 35,000 | (1) | $ | 333,932 | (1) | |||||||
May 1-31 | — | — | — | — | |||||||||||
June 1-30 | — | — | — | — | |||||||||||
Total | 35,000 | (2) | $ | 144.21 | (2) | 35,000 | $ | 333,932 | |||||||
ITEM 6. | EXHIBITS |
Exhibit Number | Exhibit Description |
3.1 | |
15.1 | |
31.1 | |
31.2 | |
32.1 | |
101.SCH | Inline Schema Document. |
101.CAL | Inline Calculation Linkbase Document. |
101.DEF | Inline Definition Linkbase Document. |
101.LAB | Inline Labels Linkbase Document. |
101.PRE | Inline Presentation Linkbase Document. |
104 | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
STERIS plc |
/s/ KAREN L. BURTON |
Karen L. Burton Vice President, Controller and Chief Accounting Officer |
August 7, 2020 |
Registration Number | Description | |
333-230557 | Form S-8 Registration Statement of STERIS plc pertaining to the STERIS Corporation 401(k) Plan | |
333-230558 | Form S-8 Registration Statement of STERIS plc pertaining to the STERIS plc 2006 Long-Term Equity Incentive Plan (As Assumed, Amended and Restated Effective March 28, 2019) | |
1. | I have reviewed this quarterly report on Form 10-Q of STERIS plc; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Date: | August 7, 2020 |
/s/ WALTER M ROSEBROUGH, JR | |
Walter M Rosebrough, Jr. President and Chief Executive Officer | |
1. | I have reviewed this quarterly report on Form 10-Q of STERIS plc; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations, and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and |
5. | The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions): |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize, and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting. |
Date: | August 7, 2020 |
/s/ MICHAEL J. TOKICH | |
Michael J. Tokich Senior Vice President and Chief Financial Officer | |
(1) | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
(2) | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company as of the dates and for the periods expressed in the Report. |
/s/ WALTER M ROSEBROUGH, JR | ||
Name: | Walter M Rosebrough, Jr. | |
Title: | President and Chief Executive Officer | |
/s/ MICHAEL J. TOKICH | ||
Name: | Michael J. Tokich | |
Title: | Senior Vice President and Chief Financial Officer | |
CONSOLIDATED BALANCE SHEETS (unaudited) Consolidated Balance Sheet (Parenthetical) - USD ($) $ in Thousands |
Jun. 30, 2020 |
Mar. 31, 2020 |
|---|---|---|
| Accounts Receivable, Allowance for Credit Loss, Current | $ 10,839 | $ 12,051 |
| Preferred Stock, Shares Authorized | 50,000,000 | |
| Preferred Stock, Par or Stated Value Per Share | $ 0.001 | |
| Common Stock, Shares Authorized | $ 500,000 | $ 500,000 |
| Common Stock, Shares, Issued | 500,000,000 | 500,000,000 |
| Common Stock, Shares, Outstanding | 85,060,000 | 84,924,000 |
| Common Stock, Par or Stated Value Per Share | $ 0.001 | $ 0.001 |
| Intangible Assets, Net (Excluding Goodwill) | $ 551,526 | $ 565,473 |
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (unaudited) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Net Income | $ 88,124 | $ 84,777 |
| Less: Net Income Attributable to Noncontrolling Interest | (66) | 187 |
| Net income (loss) attributable to shareholders | 88,190 | 84,590 |
| Other comprehensive (loss) income | ||
| Amortization of pension and postretirement benefits plans costs, (net of taxes of $170 and $169, respectively) | (510) | (505) |
| Change in cumulative foreign current translation adjustment | 27,619 | 3,439 |
| Total other comprehensive (loss) income | 27,109 | 2,934 |
| Comprehensive income | 115,299 | 87,524 |
| Other comprehensive (loss) income (parenthetical) | ||
| Amortization of pension and postretirement benefits plans costs, tax | $ 174 | $ 170 |
CONSOLIDATED STATEMENT OF SHAREHOLDERS' EQUITY Statement - USD ($) shares in Thousands, $ in Thousands |
Total |
Noncontrolling Interest [Member] |
AOCI Attributable to Parent [Member] |
Retained Earnings [Member] |
Common Stock [Member] |
|---|---|---|---|---|---|
| Shares, Issued | 84,517 | ||||
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | $ 3,185,798 | $ 7,988 | $ (159,778) | $ 1,339,024 | $ 1,998,564 |
| Common Stock, Dividends, Per Share, Cash Paid | $ 0.34 | ||||
| Net Income (Loss) Attributable to Parent | $ 84,590 | 0 | 84,590 | $ 0 | |
| Net Income (Loss) Attributable to Noncontrolling Interest | 187 | 187 | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | 84,777 | ||||
| Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | 2,934 | 2,934 | |||
| Treasury Stock, Shares, Acquired | (127) | ||||
| Payments for Repurchase of Common Stock | (14,886) | 0 | 2,599 | $ (17,485) | |
| Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture | 364 | ||||
| Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture | 15,275 | 0 | 0 | 0 | $ 15,275 |
| Dividends, Common Stock, Cash | (28,823) | 0 | 0 | (28,823) | 0 |
| Noncontrolling Interest, Change in Redemption Value | (73) | (73) | 0 | 0 | $ 0 |
| Shares, Issued | 84,754 | ||||
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | 3,245,002 | ||||
| Stockholders' Equity Attributable to Parent | (156,844) | 1,397,390 | $ 1,996,354 | ||
| Stockholders' Equity Attributable to Noncontrolling Interest | 8,102 | ||||
| Shares, Issued | 84,924 | ||||
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | 3,406,724 | 12,848 | (235,463) | 1,647,175 | $ 1,982,164 |
| Stockholders' Equity Attributable to Parent | 3,393,876 | ||||
| Stockholders' Equity Attributable to Noncontrolling Interest | $ 12,848 | ||||
| Common Stock, Dividends, Per Share, Cash Paid | $ 0.37 | ||||
| Net Income (Loss) Attributable to Parent | $ 88,190 | 0 | 88,190 | $ 0 | |
| Net Income (Loss) Attributable to Noncontrolling Interest | (66) | (66) | |||
| Net Income (Loss), Including Portion Attributable to Noncontrolling Interest | 88,124 | ||||
| Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent | 27,109 | 27,109 | |||
| Treasury Stock, Shares, Acquired | (98) | ||||
| Payments for Repurchase of Common Stock | (14,296) | 0 | (3,923) | $ (10,373) | |
| Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture | 234 | ||||
| Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture | 11,256 | 0 | 0 | 0 | $ 11,256 |
| Dividends, Common Stock, Cash | (31,471) | 0 | 0 | (31,471) | 0 |
| Contributions from noncontrolling interest | (2,258) | 2,258 | |||
| Noncontrolling Interest, Change in Redemption Value | 9 | 9 | 0 | 0 | $ 0 |
| Shares, Issued | 85,060 | ||||
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | 3,489,713 | ||||
| Stockholders' Equity Attributable to Parent | 3,474,664 | $ (208,354) | $ 1,699,971 | $ 1,983,047 | |
| Stockholders' Equity Attributable to Noncontrolling Interest | $ 15,049 | $ 15,049 |
Nature of Operations and Summary of Significant Accounting Policies(Notes) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes To Financial Statements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Nature of Operations | Nature of Operations and Summary of Significant Accounting Policies Nature of Operations STERIS plc is a leading provider of infection prevention and other procedural products and services. Our MISSION IS TO HELP OUR CUSTOMERS CREATE A HEALTHIER AND SAFER WORLD by providing innovative healthcare and life science product and service solutions around the globe. We offer our Customers a unique mix of innovative consumable products, such as detergents, gastrointestinal ("GI") endoscopy accessories, barrier product solutions, and other products and services, including: equipment installation and maintenance, microbial reduction of medical devices, instrument and scope repair solutions, laboratory testing services, on-site and off-site reprocessing, and capital equipment products, such as sterilizers and surgical tables, and connectivity solutions such as operating room (“OR”) integration. Our fiscal year ends on March 31. References in this Quarterly Report to a particular “year” or “year-end” mean our fiscal year. The significant accounting policies applied in preparing the accompanying consolidated financial statements of the Company are summarized below: Interim Financial Statements We prepared the accompanying unaudited consolidated financial statements of the Company according to accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and the instructions to the Quarterly Report on Form 10-Q and Rule 10-01 of Regulation S-X. This means that they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Our unaudited interim consolidated financial statements contain all material adjustments (including normal recurring accruals and adjustments) management believes are necessary to fairly state our financial condition, results of operations, and cash flows for the periods presented. These interim consolidated financial statements should be read together with the consolidated financial statements and related notes included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. The Consolidated Balance Sheet at March 31, 2020 was derived from the audited consolidated financial statements at that date, but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements. Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021. Revenue Recognition and Associated Liabilities We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter. Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancelable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal 2021, $30,804 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2020, $39,484 of the March 31, 2019 deferred revenue balance was recorded as revenue. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancelable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of June 30, 2020, the transaction price allocated to remaining performance obligations was approximately $930,000. We expect to recognize approximately 48% of the transaction price within one year and approximately 46% beyond one year. The remainder has yet to be scheduled for delivery. Recently Issued Accounting Standards Impacting the Company Recently Issued Accounting Standards Impacting the Company are presented in the following table:
A detailed description of our significant and critical accounting policies, estimates, and assumptions is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020. Our significant and critical accounting policies, estimates, and assumptions have not changed materially from March 31, 2020.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories, Net (Notes) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventories, Net | Inventories, Net We use the last-in, first-out (“LIFO”) and first-in, first-out (“FIFO”) cost methods to value inventory. Inventory valued using the LIFO cost method is stated at the lower of cost or market. Inventory valued using the FIFO cost method is stated at the lower of cost or net realizable value. An actual valuation of inventory under the LIFO method is made only at the end of the fiscal year based on the inventory levels and costs at that time. Accordingly, interim LIFO calculations are based on management’s estimates of expected year-end inventory levels and are subject to the final fiscal year-end LIFO inventory valuation. Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment | Property, Plant and Equipment Information related to the major categories of our depreciable assets is as follows:
(1) Land is not depreciated. Construction in progress is not depreciated until placed in service.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt | Debt Indebtedness was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Consolidated Balance Sheets Information (Notes) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes To Financial Statements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Additional Consolidated Balance Sheets Information | Additional Consolidated Balance Sheet Information Additional information related to our Consolidated Balance Sheets is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Income Tax Expense (Notes) |
3 Months Ended |
|---|---|
Jun. 30, 2020 | |
| Income Tax Disclosure [Abstract] | |
| Income Tax Expense | Income Tax Expense The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017. The TCJA reduced the U.S. federal corporate income tax rate to 21.0%, required companies to pay a one-time transition tax on earnings of certain foreign subsidiaries that were previously tax deferred and created new taxes on certain foreign sourced earnings. The Company applied the guidance in Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cut and Jobs Act when accounting for the enactment-date effects of the TCJA. We consider the tax expense recorded for the TCJA to be complete at this time. However, it is possible that additional legislation, regulations and/or guidance may be issued in the future that may result in additional adjustments to the tax expense recorded related to the TCJA. We will continue to monitor and assess the impact of any new developments. The effective income tax rates for the three month periods ended June 30, 2020 and 2019 were 17.5% and 14.7%, respectively. The fiscal 2021 effective tax rate increased when compared to fiscal 2020 primarily due to an increased percentage of profits earned and taxed in jurisdictions with a higher tax rate. Income tax expense is provided on an interim basis based upon our estimate of the annual effective income tax rate, adjusted each quarter for discrete items. In determining the estimated annual effective income tax rate, we analyze various factors, including projections of our annual earnings and taxing jurisdictions in which the earnings will be generated, the impact of state and local income taxes, our ability to use tax credits and net operating loss carry forwards, and available tax planning alternatives. We operate in numerous taxing jurisdictions and are subject to regular examinations by various United States federal, state and local, as well as foreign jurisdictions. We are no longer subject to United States federal examinations for years before fiscal 2016 and, with limited exceptions, we are no longer subject to United States state and local, or non-United States, income tax examinations by tax authorities for years before fiscal 2015. We remain subject to tax authority audits in various jurisdictions wherever we do business. In May 2019, we received two notices of proposed tax adjustment from the U.S. Internal Revenue Service (the “IRS”) regarding the deductibility of interest paid on certain intercompany debt. The notices relate to fiscal years 2016 and 2017. In September 2019, we received another notice of proposed adjustment for the same issue, for the 2018 fiscal year. The IRS adjustments would result in a cumulative tax liability of approximately $40,000. Notices have not been received for subsequent periods. We are contesting the IRS’s assertions, and intend to pursue available remedies such as appeals and litigation, if necessary. We have not established reserves related to these notices. An unfavorable outcome is not expected to have a material adverse impact on our consolidated financial position but could be material to our consolidated results of operations and cash flows for any one period.
|
Business Segment Information (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Segment Reporting [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Segment Information | Business Segment Information We operate and report our financial information in three reportable business segments: Healthcare, Applied Sterilization Technologies and Life Sciences. Non-allocated operating costs that support the entire Company and items not indicative of operating trends are excluded from segment operating income. Prior to April 1, 2020, we operated and reported our financial information in four reportable business segments: Healthcare Products, Healthcare Specialty Services, Life Sciences, and Applied Sterilization Technologies. The Healthcare Products and Healthcare Specialty Services segments were combined and are now reported as one segment, simply called Healthcare, consistent with the way management now operates and views the business. Prior periods have been recasted in the financial tables below for comparability. Our Healthcare segment offers infection prevention and procedural solutions for healthcare providers worldwide, including consumable products, equipment maintenance and installation services, and capital equipment. The segment also provides a range of specialty services for healthcare providers including hospital sterilization services and instrument and scope repairs. Our Applied Sterilization Technologies ("AST") segment provides contract sterilization and testing services for medical device and pharmaceutical manufacturers. Our Life Sciences segment designs, manufactures and sells consumable products, equipment maintenance, specialty services and capital equipment primarily to pharmaceutical manufacturers around the world. We disclose a measure of segment income that is consistent with the way management operates and views the business. The accounting policies for reportable segments are the same as those for the consolidated Company. For the three months ended June 30, 2020, revenues from a single Customer did not represent ten percent or more of any reportable segment’s revenues. Additional information regarding our segments is included in our consolidated financial statements included in our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020. Financial information for each of our segments is presented in the following table:
(1) For more information regarding our recent acquisitions and divestitures refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020. (2) Acquisition and integration related charges include transaction costs and integration expenses associated with acquisitions. (3) Costs incurred in connection with the Redomiciliation. (4) COVID-19 incremental costs includes the additional costs attributable to COVID-19 such as enhanced cleaning protocols, personal protective equipment for our employees, event cancellation fees, and payroll costs associated with our response to COVID-19, net of any government subsidies available. (5) For more information regarding our restructuring efforts refer to Note 2 titled, "Restructuring". Additional information regarding our fiscal 2021 and fiscal 2020 first quarter revenue is disclosed in the following tables:
Assets include the current and long-lived assets directly attributable to the segment based on the management of the location or on utilization. Certain corporate assets were allocated to the reportable segments based on revenues. Assets attributed to sales and distribution locations are only allocated to the Healthcare and Life Sciences segments. Individual facilities, equipment, and intellectual properties are utilized for production by both the Healthcare and Life Sciences segments at varying levels over time. As a result, an allocation of total assets, capital expenditures, and depreciation and amortization is not meaningful to the individual performance of the Healthcare and Life Sciences segments. Therefore, their respective amounts are reported together.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares and Preferred Shares (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share | Ordinary shares We calculate basic earnings per share based upon the weighted average number of shares outstanding. We calculate diluted earnings per share based upon the weighted average number of shares outstanding plus the dilutive effect of share equivalents calculated using the treasury stock method. The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:
Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:
Additional Authorized Shares The Company has an additional authorized share capital of 50,000,000 preferred shares of $0.001 par value each, plus 25,000 deferred ordinary shares of €1.00 par value each, in order to satisfy minimum statutory capital requirements for all Irish public limited companies.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Repurchases of Shares (Notes) |
3 Months Ended |
|---|---|
Jun. 30, 2020 | |
| Notes To Financial Statements [Abstract] | |
| Repurchases of shares | Repurchases of Ordinary Shares On May 7, 2019, our Board of Directors authorized a share repurchase program resulting in a share repurchase authorization of approximately $78,979 (net of taxes, fees and commissions). On July 30, 2019, our Board of Directors approved an increase in the May 7, 2019 authorization of an additional amount of $300,000 (net of taxes, fees and commissions). As of June 30, 2020, there was approximately $333,932 (net of taxes, fees and commissions) of remaining availability under a Board authorized share repurchase program. The share repurchase program has no specified expiration date. Under the authorization, the Company may repurchase its shares from time to time through open market purchases, including 10b5-1 plans. Any share repurchases may be activated, suspended or discontinued at any time. Due to the uncertainty surrounding the COVID-19 pandemic, share repurchases were suspended on April 9, 2020. During the first three months of fiscal 2021 through April 9, 2020, we repurchased 35,000 of our ordinary shares for the aggregate amount of $5,047 (net of fees and commissions) pursuant to the authorizations. During the first three months of fiscal 2020, we repurchased 60,000 of our ordinary shares for the aggregate amount of $8,612 (net of fees and commissions) pursuant to the authorizations. During the first three months of fiscal 2021 we obtained 63,150 of our ordinary shares in the aggregate amount of $9,248 in connection with share based compensation award programs. During the first three months of fiscal 2020, we obtained 66,745 of our ordinary shares in the aggregate amount of $7,446 in connection with share based compensation award programs.
|
Share-Based Compensation (Notes) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Payment Arrangement [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-Based Compensation | Share-Based Compensation We maintain a long-term incentive plan that makes available shares for grants, at the discretion of the Compensation Committee of the Board of Directors, to officers, directors, and key employees in the form of stock options, restricted shares, restricted share units, stock appreciation rights and share grants. We satisfy share award incentives through the issuance of new ordinary shares. Stock options provide the right to purchase our shares at the market price on the date of grant, or for options granted to employees in fiscal 2019 and thereafter, 110% of the market price on the date of grant, subject to the terms of the option plan and agreements. Generally, one-fourth of the stock options granted to employees become exercisable for each full year of employment following the grant date. Stock options granted generally expire 10 years after the grant date, or in some cases earlier if the option holder is no longer employed by us. Restricted shares and restricted share units generally cliff vest after a four year period or vest in tranches of one-fourth of the number granted for each year of employment after the grant date. As of June 30, 2020, 3,554,149 ordinary shares remained available for grant under the long-term incentive plan. The fair value of stock option awards was estimated at their grant date using the Black-Scholes-Merton option pricing model. This model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable, characteristics that are not present in our option grants. If the model permitted consideration of the unique characteristics of employee stock options, the resulting estimate of the fair value of the stock options could be different. The value of the portion of the award that is ultimately expected to vest is recognized as expense over the requisite service periods in our Consolidated Statements of Income. The expense is classified as cost of goods sold or selling, general and administrative expenses in a manner consistent with the employee’s compensation and benefits. The following weighted-average assumptions were used for options granted during the first three months of fiscal 2021 and 2020:
The risk-free interest rate is based upon the U.S. Treasury yield curve. The expected life of options is reflective of historical experience, vesting schedules and contractual terms. The expected dividend yield of stock represents our best estimate of the expected future dividend yield. The expected volatility of stock is derived by referring to our historical stock prices over a time frame similar to that of the expected life of the grant. An estimated forfeiture rate of 2.78% and 2.77% was applied in fiscal 2021 and 2020, respectively. This rate is calculated based upon historical activity and represents an estimate of the granted options not expected to vest. If actual forfeitures differ from this calculated rate, we may be required to make additional adjustments to compensation expense in future periods. The assumptions used above are reviewed at the time of each significant option grant, or at least annually. A summary of share option activity is as follows:
We estimate that 772,889 of the non-vested stock options outstanding at June 30, 2020 will ultimately vest. The aggregate intrinsic value in the table above represents the total pre-tax difference between the $153.44 closing price of our ordinary shares on June 30, 2020 over the exercise prices of the stock options, multiplied by the number of options outstanding or outstanding and exercisable, as applicable. The aggregate intrinsic value is not recorded for financial accounting purposes and the value changes daily based on the daily changes in the fair market value of ordinary shares. The total intrinsic value of stock options exercised during the first three months of fiscal 2021 and fiscal 2020 was $9,581 and $18,843, respectively. Net cash proceeds from the exercise of stock options were $5,367 and $9,899 for the first three months of fiscal 2021 and fiscal 2020, respectively. The weighted average grant date fair value of stock option grants was $27.44 and $23.19 for the first three months of fiscal 2021 and fiscal 2020, respectively. Stock appreciation rights (“SARS”) carry generally the same terms and vesting requirements as stock options except that they are settled in cash upon exercise and therefore, are classified as liabilities. The fair value of the outstanding SARS as of June 30, 2020 and 2019 was $493 and $610, respectively. A summary of the non-vested restricted share and share unit activity is presented below:
Restricted shares granted are valued based on the closing stock price at the grant date. The value of restricted shares and units that vested during the first three months of fiscal 2021 was $12,902. As of June 30, 2020, there was a total of $63,875 in unrecognized compensation cost related to non-vested share-based compensation granted under our share-based compensation plan. We expect to recognize the cost over a weighted average period of 2.4 years.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial and Other Guarantees(Notes) |
3 Months Ended | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||
| Product Warranties Disclosures [Abstract] | |||||||||||||||||||||||||||||
| Commitments Contingencies and Guarantees [Text Block] | Commitments and Contingencies We are, and will likely continue to be, involved in a number of legal proceedings, government investigations, and claims, which we believe generally arise in the course of our business, given our size, history, complexity, and the nature of our business, products, Customers, regulatory environment, and industries in which we participate. These legal proceedings, investigations and claims generally involve a variety of legal theories and allegations, including, without limitation, personal injury (e.g., slip and falls, burns, vehicle accidents), product liability or regulation (e.g., based on product operation or claimed malfunction, failure to warn, failure to meet specification, or failure to comply with regulatory requirements), product exposure (e.g., claimed exposure to chemicals, asbestos, contaminants, radiation), property damage (e.g., claimed damage due to leaking equipment, fire, vehicles, chemicals), commercial claims (e.g., breach of contract, economic loss, warranty, misrepresentation), financial (e.g., taxes, reporting), employment (e.g., wrongful termination, discrimination, benefits matters), and other claims for damage and relief. We believe we have adequately reserved for our current litigation and claims that are probable and estimable, and further believe that the ultimate outcome of these pending lawsuits and claims will not have a material adverse effect on our consolidated financial position or results of operations taken as a whole. Due to their inherent uncertainty, however, there can be no assurance of the ultimate outcome or effect of current or future litigation, investigations, claims or other proceedings (including without limitation the matters discussed below). For certain types of claims, we presently maintain insurance coverage for personal injury and property damage and other liability coverages in amounts and with deductibles that we believe are prudent, but there can be no assurance that these coverages will be applicable or adequate to cover adverse outcomes of claims or legal proceedings against us. Civil, criminal, regulatory or other proceedings involving our products or services could possibly result in judgments, settlements or administrative or judicial decrees requiring us, among other actions, to pay damages or fines or effect recalls, or be subject to other governmental, Customer or other third party claims or remedies, which could materially effect our business, performance, prospects, value, financial condition, and results of operations. For additional information regarding these matters, see the following portions of our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020: Item 1 titled “Business - Information with respect to our Business in General - Government Regulation”, and the “Risk Factors” in Item 1A titled "Product related regulations and claims". From time to time, STERIS is also involved in legal proceedings as a plaintiff involving contract, patent protection, and other claims asserted by us. Gains, if any, from these proceedings are recognized when they are realized. We are subject to taxation from United States federal, state and local, and non-U.S. jurisdictions. Tax positions are settled primarily through the completion of audits within each individual jurisdiction or the closing of statutes of limitation. Changes in applicable tax law or other events may also require us to revise past estimates. We describe income taxes further in Note 7 to our consolidated financial statements titled, “Income Tax Expense” in this Quarterly Report on Form 10-Q.
|
||||||||||||||||||||||||||||
| Product Warranty Disclosure | Financial and Other Guarantees We generally offer a limited parts and labor warranty on capital equipment. The specific terms and conditions of those warranties vary depending on the product sold and the countries where we conduct business. We record a liability for the estimated cost of product warranties at the time product revenues are recognized. The amounts we expect to incur on behalf of our Customers for the future estimated cost of these warranties are recorded as a current liability on the accompanying Consolidated Balance Sheets. Factors that affect the amount of our warranty liability include the number and type of installed units, historical and anticipated rates of product failures, and material and service costs per claim. We periodically assess the adequacy of our recorded warranty liabilities and adjust the amounts as necessary. Changes in our warranty liability during the first three months of fiscal 2021 were as follows:
|
||||||||||||||||||||||||||||
Derivatives and Hedging (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure | Derivatives and Hedging From time to time, we enter into forward contracts to hedge potential foreign currency gains and losses that arise from transactions denominated in foreign currencies, including inter-company transactions. We may also enter into commodity swap contracts to hedge price changes in nickel that impact raw materials included in our cost of revenues. During the first quarter of fiscal 2021, we also entered into forward foreign currency contracts in order to hedge a portion of our expected non-U.S. dollar denominated earnings against our reporting currency, the U.S. dollar. These foreign currency exchange contracts will mature during fiscal 2021. We did not elect hedge accounting for these forward foreign currency contracts; however, we may seek to apply hedge accounting in future scenarios. We do not use derivative financial instruments for speculative purposes. None of these contracts are designated as hedging instruments and do not receive hedge accounting treatment; therefore, changes in their fair value are not deferred but are recognized immediately in the Consolidated Statements of Income. At June 30, 2020, we held foreign currency forward contracts to buy 99.0 million Mexican pesos, 6.3 million Canadian dollars; and to sell 11.3 million euros. At June 30, 2020 we held commodity swap contracts to buy 536.4 thousand pounds of nickel.
The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:
Additionally, we hold our debt in multiple currencies to fund our operations and investments in certain subsidiaries. We designate portions of foreign currency denominated intercompany loans as hedges of portions of net investments in foreign operations. Net debt designated as non-derivative net investment hedging instruments totaled $46,698 at June 30, 2020. These hedges are designed to be fully effective and any associated gain or loss is recognized in Accumulated Other Comprehensive Income and will be reclassified to income in the same period when a gain or loss related to the net investment in the foreign operation is included in income.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements (Notes) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Measurement and Measurement Inputs, Recurring and Nonrecurring [Text Block] | Fair Value Measurements Fair value is defined as the price that would be received to sell an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. We estimate the fair value of financial assets and liabilities using available market information and generally accepted valuation methodologies. The inputs used to measure fair value are classified into three tiers. These tiers include Level 1, defined as observable inputs such as quoted prices in active markets; Level 2, defined as inputs other than quoted prices in active markets that are either directly or indirectly observable; and Level 3, defined as unobservable inputs in which little or no market data exists, therefore requiring the entity to develop its own assumptions. The following table shows the fair value of our financial assets and liabilities at June 30, 2020 and March 31, 2020:
(1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the first quarter of fiscal 2021 and 2020, we recorded a gains (losses) of $309 and $(1,758), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at June 30, 2020 are summarized as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Notes) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassifications out of AOCI [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Comprehensive Income (Loss) Note [Text Block] | Reclassifications Out of Accumulated Other Comprehensive Income (Loss) Amounts in Accumulated Other Comprehensive Income (Loss) are presented net of the related tax. Currency Translation is not adjusted for income taxes. Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended June 30, 2020 and 2019 were as follows:
(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
(1) Amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Loans Receivable (Notes) |
3 Months Ended |
|---|---|
Jun. 30, 2020 | |
| Receivables [Abstract] | |
| Loans, Notes, Trade and Other Receivables Disclosure [Text Block] | 17. Loans Receivable In connection with an equity investment of $4,955, we agreed to provide a credit facility of up to approximately $11,000 for a term of up to seven years ending in 2025. The loan carries an interest rate of 4% compounded daily and payable annually. Outstanding borrowings under the agreement totaled $7,316 at June 30, 2020 and $7,084 at March 31, 2020. In connection with the fiscal 2017 divestiture of Synergy Health Netherlands Linen Management Services, we entered into a loan agreement to provide financing of up to €15,000 for a term of up to 15 years. The loan carried an interest rate of 4% for the first four years and 12% thereafter. The loan was renegotiated during the third quarter of fiscal 2020. According to the new terms of the loan agreement, the outstanding balance at October 31, 2019, of €7,300, will be repaid in six equal annual installments beginning on October 18, 2022. The loan carries an interest rate of 4% for the first four years and 8% thereafter. Outstanding borrowings under the agreement totaled $8,210 (or €7,300) at June 30, 2020 and $8,072 (or €7,300) at March 31, 2020. Amounts for loan receivables as noted above are recorded in the "Other assets" line of our Consolidated balance sheets. Interest income is not material
|
Restructuring (Notes) |
3 Months Ended |
|---|---|
Jun. 30, 2020 | |
| Restructuring [Abstract] | |
| Restructuring and Related Activities Disclosure [Text Block] | Restructuring Fiscal 2019 Restructuring Plan. During the third quarter of fiscal 2019, we adopted and announced a targeted restructuring plan (the "Fiscal 2019 Restructuring Plan"), which included the closure of two manufacturing facilities, one in Brazil and one in England, as well as other actions including the rationalization of certain products. Fewer than 200 positions were eliminated. The Company relocated the production of certain impacted products to other existing manufacturing operations during fiscal 2020. These restructuring actions were designed to enhance profitability and improve efficiency. Since inception of the Fiscal 2019 Restructuring Plan we have incurred pre-tax expenses totaling $44,017 related to these restructuring actions, of which $31,826 was recorded as restructuring expenses and $12,191 was recorded in cost of revenues, with a total of $33,819, $7,798 and $668 related to the Healthcare, Applied Sterilization Technologies and Life Sciences segments, respectively. Corporate related restructuring charges were $1,732. Additional restructuring expenses related to this plan are not expected to be material to our results of operations. Liabilities related to restructuring activities are recorded as current liabilities on the accompanying Consolidated Balance Sheets within “Accrued payroll and other related liabilities” and “Accrued expenses and other.” The remaining liability balances at June 30, 2020 and March 31, 2020 are not material. For more information relating to our restructuring efforts, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020, dated May 29, 2020.
|
COVID-19 Pandemic (Notes) |
3 Months Ended |
|---|---|
Jun. 30, 2020 | |
| Statement of Financial Position [Abstract] | |
| COVID-19 Pandemic [Text Block] | COVID-19 Pandemic The COVID-19 pandemic began to impact our business late in fiscal 2020. The pandemic and related public health recommendations and mandated precautions to mitigate the spread of COVID-19, including deferral of medical procedures and treatments and shelter-in-place orders or similar measures, have negatively affected and are expected to continue to negatively affect some of our operations, which may impact our financial position and cash flows. We have experienced and expect to continue to experience unpredictable fluctuations in demand for certain of our products and services, including some products and services that are experiencing increased demand. To date, we do not believe that the COVID-19 pandemic has had a significant impact on our operations, as we have been able to continue to operate our manufacturing facilities and meet the demand for essential products and services of our Customers. In response to the pandemic, we have implemented several measures that we believe will help us to protect the health and safety of our employees, preserve liquidity and enhance our financial flexibility. For our employees, we allowed employees to work remotely when possible and have implemented additional safety measures in compliance with applicable regulations to allow personnel to continue to work in our facilities. We suspended all non-essential travel and enacted a temporary hiring freeze on certain positions. To manage liquidity, we have suspended our stock repurchase program and deferred certain planned capital expenditures; however, we have continued to invest in expansion projects as planned. We do not believe that these actions will negatively impact our long-term ability to generate revenues or meet existing and future financial obligations. While we expect this situation to have an impact on our business, the full impact to our results of operations and financial position cannot be reasonably estimated at this time. For additional information and our risk factors related to the COVID-19 pandemic, please refer to our Annual Report on Form 10-K for the year ended March 31, 2020 dated May 29, 2020.
|
Nature of Operations and Summary of Significant Accounting Policies Accounting Policies (Policies) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Accounting Policies [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Principles of Consolidation | Principles of Consolidation We use the consolidation method to report our investment in our subsidiaries. Therefore, the accompanying consolidated financial statements include the accounts of the Company and its wholly-owned and majority-owned subsidiaries. We eliminate inter-company accounts and transactions when we consolidate these accounts. Investments in equity of unconsolidated affiliates, over which the Company has significant influence, but not control, over the financial and operating polices, are accounted for primarily using the equity method. These investments are immaterial to the Company's Consolidated Financial Statements.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Use of Estimates | Use of Estimates We make certain estimates and assumptions when preparing financial statements according to U.S. GAAP that affect the reported amounts of assets and liabilities at the financial statement dates and the reported amounts of revenues and expenses during the periods presented. These estimates and assumptions involve judgments with respect to many factors that are difficult to predict and are beyond our control. Actual results could be materially different from these estimates. We revise the estimates and assumptions as new information becomes available. This means that operating results for the three month period ended June 30, 2020 are not necessarily indicative of results that may be expected for future quarters or for the full fiscal year ending March 31, 2021.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recently Issued Accounting Standards Impacting the Company | Recently Issued Accounting Standards Impacting the Company are presented in the following table:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue from Contract with Customer [Policy Text Block] | Revenue Recognition and Associated Liabilities We adopted Accounting Standards Update ("ASU") 2014-09 “Revenue from Contracts with Customers” and the subsequently issued amendments on April 1, 2018. At the time of adoption, certain of our capital equipment contracts were comprised of a single integrated performance obligation, which resulted in the deferral of the corresponding capital equipment revenue and cost of revenues until installation was complete. Since the adoption of the standard, there have been changes made in our selling philosophy, product architecture, and manufacturing processes with respect to this product line, that impact whether the promises to transfer the individual goods or services to the Customer are separately identifiable from other promises in the contract. After review of these changes, we have concluded that these contracts consist of multiple performance obligations that are capable of being distinct and meet the criteria for revenue to be recognized when the Customer obtains control of the asset, which is upon delivery of each performance obligation. Revenues and costs of revenues related to these contracts totaling $14,609 and $7,560, respectively, that had previously been deferred were recognized in our fiscal 2021 first quarter. Revenue is recognized when obligations under the terms of the contract are satisfied and control of the promised products or services have transferred to the Customer. Revenues are measured at the amount of consideration that we expect to be paid in exchange for the products or services. Product revenue is recognized when control passes to the Customer, which is generally based on contract or shipping terms. Service revenue is recognized when the Customer benefits from the service, which occurs either upon completion of the service or as it is provided to the Customer. Our Customers include end users as well as dealers and distributors who market and sell our products. Our revenue is not contingent upon resale by the dealer or distributor, and we have no further obligations related to bringing about resale. Our standard return and restocking fee policies are applied to sales of products. Shipping and handling costs charged to Customers are included in Product revenues. The associated expenses are treated as fulfillment costs and are included in Cost of revenues. Revenues are reported net of sales and value-added taxes collected from Customers. We have individual Customer contracts that offer discounted pricing. Dealers and distributors may be offered sales incentives in the form of rebates. We reduce revenue for discounts and estimated returns, rebates, and other similar allowances in the same period the related revenues are recorded. The reduction in revenue for these items is estimated based on historical experience and trend analysis to the extent that it is probable that a significant reversal of revenue will not occur. Estimated returns are recorded gross on the Consolidated Balance Sheets. In transactions that contain multiple performance obligations, such as when products, maintenance services, and other services are combined, we recognize revenue as each product is delivered or service is provided to the Customer. We allocate the total arrangement consideration to each performance obligation based on its relative standalone selling price, which is the price for the product or service when it is sold separately. Payment terms vary by the type and location of the Customer and the products or services offered. Generally, the time between when revenue is recognized and when payment is due is not significant. We do not evaluate whether the selling price contains a financing component for contracts that have a duration of less than one year. We do not capitalize sales commissions as substantially all of our sales commission programs have an amortization period of one year or less. Certain costs to fulfill a contract are capitalized and amortized over the term of the contract if they are recoverable, directly related to a contract and generate resources that we will use to fulfill the contract in the future. At June 30, 2020, assets related to costs to fulfill a contract were not material to our Consolidated Financial Statements. Refer to Note 9, titled "Business Segment Information" for disaggregation of revenue. Product Revenue Product revenues consist of revenues generated from sales of consumables and capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer or Group Purchasing Organization ("GPO") agreement. We recognize revenue for sales of product when control passes to the Customer, which generally occurs either when the products are shipped or when they are received by the Customer. Revenue related to capital equipment products is deferred until installation is complete if the capital equipment and installation are highly integrated and form a single performance obligation. Service Revenue Within our Healthcare and Life Sciences segments, service revenues consist of revenue generated from parts and labor associated with the maintenance, repair and installation of capital equipment. These contracts are primarily based on a Customer’s purchase order and may include a Distributor, Dealer, or Group Purchasing Organization ("GPO") agreement. For maintenance, repair and installation of capital equipment, revenue is recognized upon completion of the service. Healthcare service revenues also include outsourced reprocessing services and instrument repairs. Contracts for outsourced reprocessing services are primarily based on an agreement with a Customer, ranging in length from several months to 15 years. Outsourced reprocessing services revenue is recognized ratably over the contract term using a time-based input measure, adjusted for volume and other performance metrics, to the extent that it is probable that a significant reversal of revenue will not occur. Contracts for instrument repairs are primarily based on a Customer’s purchase order, and the associated revenue is recognized upon completion of the repair. We also offer preventive maintenance and separately priced extended warranty agreements to our Customers, which require us to maintain and repair our products over the duration of the contract. Generally, these contract terms are cancelable without penalty and range from one to five years. Amounts received under these Customer contracts are initially recorded as a service liability and are recognized as service revenue ratably over the contract term using a time-based input measure. Within our Applied Sterilization Technologies segment, service revenues include contract sterilization and laboratory services. Sales contracts for contract sterilization and laboratory services are primarily based on a Customer’s purchase order and associated Customer agreement and revenues are generally recognized upon completion of the service. Contract Liabilities Payments received from Customers are based on invoices or billing schedules as established in contracts with Customers. Deferred revenue is recorded when payment is received in advance of performance under the contract. Deferred revenue is recognized as revenue upon completion of the performance obligation, which generally occurs within one year. During the first three months of fiscal 2021, $30,804 of the March 31, 2020 deferred revenue balance was recorded as revenue. During the first three months of fiscal 2020, $39,484 of the March 31, 2019 deferred revenue balance was recorded as revenue. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Deferred revenue balances. Service Liabilities Payments received in advance of performance for cancelable preventive maintenance and separately priced extended warranty contracts are recorded as service liabilities. Service liabilities are recognized as revenue as performance is rendered under the contract. Refer to Note 6, titled "Additional Consolidated Balance Sheet Information" for Service liability balances. Remaining Performance Obligations Remaining performance obligations reflect only the performance obligations related to agreements for which we have a firm commitment from a Customer to purchase and exclude variable consideration related to unsatisfied performance obligations. With regard to products, these remaining performance obligations include capital equipment and consumable orders which have not shipped. With regard to service, these remaining performance obligations primarily include installation, certification, and outsourced reprocessing services. As of June 30, 2020, the transaction price allocated to remaining performance obligations was approximately $930,000. We expect to recognize approximately 48% of the transaction price within one year and approximately 46% beyond one year. The remainder has yet to be scheduled for delivery.
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Inventories, Net Inventories, Net (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Inventory | Inventory costs include material, labor, and overhead. Inventories, net consisted of the following:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment Property, Plant and Equipment (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Property, Plant and Equipment | Information related to the major categories of our depreciable assets is as follows:
(1) Land is not depreciated. Construction in progress is not depreciated until placed in service.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt Debt (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Debt | Indebtedness was as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Notes To Financial Statements [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Accrued Liabilities [Table Text Block] | Additional information related to our Consolidated Balance Sheets is as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Segment Information Business Segment Information (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Segment Reporting [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Segment Reporting Information, by Segment [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue from External Customers by Products and Services [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Revenue from External Customers by Geographic Areas [Table Text Block] |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares and Preferred Shares Shares and Preferred Shares (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Earnings Per Share [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Weighted Average Number of Shares [Table Text Block] | The following is a summary of shares and share equivalents outstanding used in the calculations of basic and diluted earnings per share:
|
|||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] | Options to purchase the following number of shares were outstanding but excluded from the computation of diluted earnings per share because the combined exercise prices, unamortized fair values, and assumed tax benefits upon exercise were greater than the average market price for the shares during the periods, so including these options would be anti-dilutive:
|
|||||||||||||||||||||||||||||||||||||||||||||||||
Share-Based Compensation Share-Based Compensation (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Share-based Payment Arrangement [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Assumptions Used | The following weighted-average assumptions were used for options granted during the first three months of fiscal 2021 and 2020:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding | A summary of share option activity is as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity | ly. A summary of the non-vested restricted share and share unit activity is presented below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial and Other Guarantees Financial and Other Gurantees (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||
| Product Warranties Disclosures [Abstract] | |||||||||||||||||||||||||||||
| Schedule of Product Warranty Liability | Changes in our warranty liability during the first three months of fiscal 2021 were as follows:
|
||||||||||||||||||||||||||||
Derivatives and Hedging Derivatives and Hedging (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Derivative Instruments and Hedging Activities Disclosure [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Derivative Instruments in Statement of Financial Position, Fair Value |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance | The following table presents the impact of derivative instruments and their location within the Consolidated Statements of Income:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements Fair Value Measurements (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] | The following table shows the fair value of our financial assets and liabilities at June 30, 2020 and March 31, 2020:
(1) The fair values of forward and swap contracts are based on period-end forward rates and reflect the value of the amount that we would pay or receive for the contracts involving the same notional amounts and maturity dates. (2) We maintain a frozen domestic non-qualified deferred compensation plan covering certain employees, which allows for the deferral of payment of previously earned compensation for an employee-specified term or until retirement or termination. Amounts deferred can be allocated to various hypothetical investment options (compensation deferrals have been frozen under the plan). We hold investments to satisfy the future obligations of the plan. Employees who made deferrals are entitled to receive distributions of their hypothetical account balances (amounts deferred, together with earnings (losses)). We also hold an investment in the common stock of Servizi Italia, S.p.A, a leading provider of integrated linen washing and outsourced sterile processing services to hospital Customers. Changes in the fair value of these investments are recorded in the "Interest income and miscellaneous expense line" of the Consolidated Statement of Income. During the first quarter of fiscal 2021 and 2020, we recorded a gains (losses) of $309 and $(1,758), respectively, related to these investments. (3) We estimate the fair value of our debt using discounted cash flow analyses, based on our current incremental borrowing rates for similar types of borrowing arrangements. (4) Contingent consideration obligations arise from business acquisitions. The fair values are based on discounted cash flow analyses reflecting the possible achievement of specified performance measures or events and captures the contractual nature of the contingencies, commercial risk, and the time value of money. Contingent consideration obligations are classified in the consolidated balance sheets as accrued expense (short-term) and other liabilities (long-term), as appropriate based on the contractual payment dates. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | The changes in Level 3 assets and liabilities measured at fair value on a recurring basis at June 30, 2020 are summarized as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reclassifications out of AOCI [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] | Changes in our Accumulated Other Comprehensive Income (Loss) balances, net of tax, for the three months ended June 30, 2020 and 2019 were as follows:
(1) The amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
(1) Amortization (gain) of defined benefit pension items is reported in the Interest income and miscellaneous expense line of our Consolidated Statements of Income. (2) The effective portion of gain or loss on net debt designated as non-derivative net investment hedging instruments is recognized in Accumulated Other Comprehensive Income and is reclassified to income in the same period when a gain or loss related to the net investment is included in income.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Nature of Operations and Summary of Significant Accounting Policies Revenue Intial Application period (Details) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Property, Plant and Equipment [Line Items] | ||
| Deferred Revenue, Revenue Recognized | $ 30,804 | $ 39,484 |
Nature of Operations and Summary of Significant Accounting Policies Revenue Table (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Mar. 31, 2020 |
Mar. 31, 2019 |
|
| Recognition of Deferred Revenue | $ 14,609 | |||
| Assets | 5,363,927 | $ 5,425,582 | ||
| Deferred Revenue, Revenue Recognized | 30,804 | $ 39,484 | ||
| Deferred Cost of Revenues, Recognized in Period | 7,560 | |||
| Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest | 3,489,713 | $ 3,245,002 | 3,406,724 | $ 3,185,798 |
| Liabilities | 1,874,214 | 2,018,858 | ||
| Accounts Receivable, after Allowance for Credit Loss, Current | 503,172 | 586,481 | ||
| Inventory, Net | 276,970 | 248,259 | ||
| Other Prepaid Expense, Current | 61,359 | 54,430 | ||
| Accrued Liabilities, Current | 180,198 | 192,183 | ||
| Retained Earnings (Accumulated Deficit) | 1,699,971 | $ 1,647,175 | ||
| Revenue, Remaining Performance Obligation, Amount | $ 930,000 | |||
| Expected recognition within the next year [Member] | ||||
| Revenue, Remaining Performance Obligation, Percentage | 48.00% | |||
| Expected recognition beyond the next year [Member] [Member] | ||||
| Revenue, Remaining Performance Obligation, Percentage | 46.00% | |||
Business Acquisitions and Divestitures Fiscal 2017 Acquisitions (Details) - USD ($) $ in Thousands |
3 Months Ended | ||
|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Mar. 31, 2020 |
|
| Business Acquisition [Line Items] | |||
| Revenues | $ 668,932 | $ 696,803 | |
| Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net [Abstract] | |||
| Goodwill | $ 2,371,789 | $ 2,356,085 | |
Business Acquisitions and Divestitures Fiscal 2017 Divestitures (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|||
| Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] | ||||
| Revenues | $ 668,932 | $ 696,803 | ||
| Pre-tax gain or loss on sale of business | [1] | $ 10 | $ 2,426 | |
| ||||
Inventories, Net Inventories, Net (Details) - USD ($) $ in Thousands |
Jun. 30, 2020 |
Mar. 31, 2020 |
|---|---|---|
| Raw materials | $ 104,557 | $ 94,321 |
| Work in process | 40,833 | 35,643 |
| Finished goods | 167,277 | 151,381 |
| LIFO reserve | (18,753) | (16,937) |
| Reserve for excess and obsolete inventory | (16,944) | (16,149) |
| Inventories, net | $ 276,970 | $ 248,259 |
Property, Plant and Equipment Property, Plant and Equipment (Details) - USD ($) $ in Thousands |
Jun. 30, 2020 |
Mar. 31, 2020 |
|---|---|---|
| Property, Plant and Equipment [Line Items] | ||
| Land and land improvements | $ 66,390 | $ 65,994 |
| Buildings and leasehold improvements | 534,095 | 531,267 |
| Machinery and equipment | 692,188 | 682,488 |
| Information systems | 180,378 | 181,112 |
| Radioisotope | 524,356 | 508,593 |
| Construction in progress | 198,600 | 159,731 |
| Total property, plant, and equipment | 2,196,007 | 2,129,185 |
| Less: accumulated depreciation and depletion | (1,047,955) | (1,017,330) |
| Property, plant, and equipment, net | $ 1,148,052 | $ 1,111,855 |
Debt Debt (Details) - USD ($) $ in Thousands |
Jun. 30, 2020 |
Mar. 31, 2020 |
|---|---|---|
| Debt Instrument [Line Items] | ||
| Short-term Debt | $ 35,000 | $ 0 |
| Private Placement | 844,765 | 878,409 |
| Deferred financing costs | 3,183 | 3,337 |
| Credit Agreement | 180,574 | 275,449 |
| Total long term debt | 1,022,156 | 1,150,521 |
| Debt, Long-term and Short-term, Combined Amount | $ 1,057,156 | $ 1,150,521 |
Additional Consolidated Balance Sheets Information Additional Consolidated Balance Sheets Information (Details) - USD ($) $ in Thousands |
Jun. 30, 2020 |
Mar. 31, 2020 |
|---|---|---|
| Accrued payroll and other related liabilities: | ||
| Compensation and related items | $ 45,787 | $ 42,205 |
| Accrued vacation/paid time off | 10,899 | 9,917 |
| Accrued bonuses | 12,621 | 53,041 |
| Accrued employee commissions | 8,876 | 19,298 |
| Other postretirement benefit obligations-current portion | 1,488 | 1,488 |
| Other employee benefit plans obligations-current portion | 2,368 | 2,312 |
| Total accrued payroll and other related liabilities | 82,039 | 128,261 |
| Accrued expenses and other: | ||
| Deferred revenues | 39,975 | 53,299 |
| Service liabilities | 45,423 | 47,505 |
| Self-insured risk reserves-current portion | 7,942 | 7,342 |
| Accrued dealer commissions | 18,841 | 15,827 |
| Accrued warranty | 7,002 | 7,381 |
| Asset retirement obligation-current portion | 908 | 2,671 |
| Other | 60,107 | 58,158 |
| Total accrued expenses and other | 180,198 | 192,183 |
| Other liabilities: | ||
| Self-insured risk reserves-long-term portion | 17,452 | 17,452 |
| Other postretirement benefit obligations-long-term portion | 9,012 | 9,880 |
| Defined benefit pension plans obligations-long-term portion | 11,632 | 10,987 |
| Other employee benefit plans obligations-long-term portion | 2,371 | 2,333 |
| Accrued long-term income taxes | 11,991 | 11,959 |
| Asset retirement obligation-long-term portion | 11,120 | 9,843 |
| Long-term liabilities, other | 22,808 | 27,892 |
| Other Liabilities, Noncurrent | $ 86,386 | $ 90,346 |
Income Tax Expense Income Tax Expense (Details) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Effective Income Tax Rate Reconciliation, Percent [Abstract] | ||
| Effective Income Tax Rate, Continuing Operations | 17.50% | 14.70% |
| Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | |
| Uncertain Tax Liability Resulting From IRS Notice | $ 40,000 | |
Contingencies Leases (Details) - USD ($) $ in Thousands |
Jun. 30, 2020 |
Mar. 31, 2020 |
|---|---|---|
| Loss Contingencies [Line Items] | ||
| Capital Lease Obligations, Current | $ 20,575 | $ 19,809 |
| Capital Lease Obligations, Noncurrent | 125,151 | 114,114 |
| Operating Lease, Right-of-Use Asset | $ 143,463 | $ 131,837 |
Business Segment Information Business Segment Information (Details) - USD ($) $ in Thousands |
3 Months Ended | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Mar. 31, 2020 |
|||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Assets | $ 5,363,927 | $ 5,425,582 | |||||||||||
| Revenues | 668,932 | $ 696,803 | |||||||||||
| Segment operating income | 114,001 | 110,088 | |||||||||||
| Restructuring Charges | [1] | 166 | 2,307 | ||||||||||
| Amortization of acquired intangible assets | [2] | 17,500 | 16,949 | ||||||||||
| Business Combination, Acquisition Related Costs | [3] | 1,286 | 1,917 | ||||||||||
| Impact of TCJA | [4] | 170 | 1,770 | ||||||||||
| Net loss on divestiture of businesses | [2] | 10 | 2,426 | ||||||||||
| Amortization of inventory and property step-up to fair value | [2] | 603 | 735 | ||||||||||
| COVID-19 incremental costs | [5] | 8,670 | 0 | ||||||||||
| Healthcare Products | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 399,658 | 445,732 | |||||||||||
| Segment operating income | 82,357 | 90,515 | |||||||||||
| Restructuring Charges | 33,819 | ||||||||||||
| Healthcare Specialty Services | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Assets | 2,607,490 | 2,705,377 | |||||||||||
| Life Sciences | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 116,912 | 96,785 | |||||||||||
| Segment operating income | 48,461 | 33,039 | |||||||||||
| Restructuring Charges | 668 | ||||||||||||
| Applied Sterilization Technologies | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Assets | 2,756,437 | $ 2,720,205 | |||||||||||
| Revenues | 152,362 | 154,286 | |||||||||||
| Segment operating income | 63,955 | 68,035 | |||||||||||
| Restructuring Charges | 7,798 | ||||||||||||
| Corporate | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Segment operating income | (52,367) | (55,397) | |||||||||||
| Segment operating income | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 668,932 | 696,803 | |||||||||||
| Segment operating income | 142,406 | 136,192 | |||||||||||
| Other foreign locations [Member] | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 162,851 | 170,543 | |||||||||||
| UNITED STATES | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 491,708 | 511,152 | |||||||||||
| UNITED KINGDOM | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 14,373 | 15,108 | |||||||||||
| Consumable revenues [Member] | Healthcare Products | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 83,754 | 116,082 | |||||||||||
| Consumable revenues [Member] | Life Sciences | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 58,842 | 44,029 | |||||||||||
| Sales Revenue, Services, Net [Member] | Healthcare Products | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 187,822 | 208,795 | |||||||||||
| Sales Revenue, Services, Net [Member] | Life Sciences | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 27,640 | 25,987 | |||||||||||
| Capital equipment revenues [Member] | Healthcare Products | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | 128,082 | 120,855 | |||||||||||
| Capital equipment revenues [Member] | Life Sciences | |||||||||||||
| Segment Reporting Information [Line Items] | |||||||||||||
| Revenues | $ 30,430 | $ 26,769 | |||||||||||
| |||||||||||||
Shares and Preferred Shares Ordinary Shares (Details) |
3 Months Ended | |||
|---|---|---|---|---|
|
Jun. 30, 2020
$ / shares
shares
|
Jun. 30, 2019
shares
|
Jun. 30, 2020
EUR (€)
shares
|
Mar. 31, 2020
$ / shares
|
|
| Weighted Average Number of Shares Outstanding Reconciliation [Abstract] | ||||
| Weighted average shares outstanding - basic | 84,959,000 | 84,638,000 | ||
| Dilutive effect of share equivalents | 717,000 | 928,000 | ||
| Weighted average shares outstanding and share equivalents - diluted | 85,676,000 | 85,566,000 | ||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
| Preferred Stock, Shares Authorized | 50,000,000 | |||
| Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.001 | $ 0.001 | ||
| Preferred Stock, Par or Stated Value Per Share | $ / shares | $ 0.001 | |||
| Deferred Ordinary Shares | 25,000 | |||
| Employee share option | ||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
| Number of share options that are antidilutive | 330,000 | 122,000 | ||
| Euro Member Countries, Euro | ||||
| Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] | ||||
| Par Value (Euros) of Deferred Ordinary Shares | € | € 1.00 | |||
Shares and Preferred Shares Preferred Shares (Details) |
Jun. 30, 2020
$ / shares
|
|---|---|
| Class of Stock [Line Items] | |
| Preferred shares, par value | $ 0.001 |
Repurchases of Shares Repurchases of Shares (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Jul. 30, 2019 |
May 07, 2019 |
|
| Equity, Class of Treasury Stock [Line Items] | ||||
| Share repurchase program, number of shares authorized | $ 333,932 | $ 300,000 | $ 78,979 | |
| Shares repurchased during period, number | 35,000 | 60,000 | ||
| Aggregate value of shares repurchased pursuant to authorization | $ 5,047 | $ 8,612 | ||
| Shares obtained in connection with share based compensation award programs | 63,150 | 66,745 | ||
| Payments for shares obtained in connection with share based compensation programs | $ 9,248 | $ 7,446 | ||
Share-Based Compensation Share-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands |
3 Months Ended | |
|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Share-based Compensation Arrangement by Share-based Payment Award [Line Item] | ||
| Remaining shares available for grant | 3,554,149 | |
| Weighted-average assumptions used for options granted: | ||
| Risk-free interest rate | 0.46% | 2.27% |
| Expected life of options | 6 years | 6 years 2 months 12 days |
| Exptected dividend yield of stock | 0.96% | 1.23% |
| Expected volatility of stock | 23.04% | 20.27% |
| Estimated forfeiture rate | 2.78% | 2.77% |
| Summary of share option activity: | ||
| Outstanding at March 31, 2017 | 1,796,126 | |
| Granted | 278,364 | |
| Exercised | (96,435) | |
| Forfeited | (1,951) | |
| Outstanding at June 30, 2017 | 1,976,104 | |
| Exercisable at June 30, 2017 | 1,173,669 | |
| Weighted average exercise price: | ||
| Outstanding at March 31, 2017 | $ 91.29 | |
| Granted | 182.22 | |
| Exercised | 59.65 | |
| Forfeited | 97.56 | |
| Outstanding at June 30, 2017 | 105.64 | |
| Exercisable at June 30, 2017 | $ 79.79 | |
| Average Remaining Contractual Term, Outstanding at June 30, 2017 | 7 years 2 months 12 days | |
| Aggregate Intrinsic Value, Outstanding at June 30, 2017 | $ 102,472 | |
| Average Remaining Contractual Term, Exercisable at June 30, 2017 | 6 years | |
| Aggregate Intrinsic Value, Exercisable at June 30, 2017 | $ 86,437 | |
| Non-vested stock options outstanding expected to vest | 772,889 | |
| Ordinary shares, closing price | $ 153.44 | |
| Total intrinsic value of stock options exercised | $ 9,581 | $ 18,843 |
| Net cash proceeds from the exercise of stock options | $ 5,367 | $ 9,899 |
| Weighted average grant date fair value of stock option grants, per share | $ 27.44 | $ 23.19 |
| Summary of non-vested restricted share activity: | ||
| Unrecognized compensation cost related to nonvested share-based compensation granted | $ 63,875 | |
| Weighted Average Period For Total Compensation Expense Not Yet Recognized | 2 years 4 months 24 days | |
| Stock Appreciation Rights (SARs) [Member] | ||
| Weighted average exercise price: | ||
| FairValueOfOutstandingStockAppreciationRights | $ 493 | $ 610 |
| Restricted Stock | ||
| Summary of non-vested restricted share activity: | ||
| Number of Restricted Shares, Non-vested at Beginning of Period | 575,830 | |
| Weighted-Average Grant Date Fair Value, Non-vested at Beginning of Period | $ 98.07 | |
| Number of Restricted Shares, Granted | 129,495 | |
| Weighted-Average Grant Date Fair Value, Granted | $ 165.30 | |
| Number of Restricted Shares, Vested | (152,741) | |
| Weighted-Average Grant Date Fair Value, Vested | $ 80.34 | |
| Number of Restricted Shares, Canceled | (4,011) | |
| Weighted-Average Grant Date Fair Value, Canceled | $ 100.80 | |
| Number of Restricted Shares, Non-vested at End of Period | 548,573 | |
| Weighted-Average Grant Date Fair Value, Non-vested at End of Period | $ 118.80 | |
| Fair Value, Share-based Payment Awards, Other than Options | $ 12,902 | |
| Restricted Stock Units (RSUs) | ||
| Summary of non-vested restricted share activity: | ||
| Number of Restricted Shares, Non-vested at Beginning of Period | 30,894 | |
| Number of Restricted Shares, Granted | 5,952 | |
| Number of Restricted Shares, Vested | (7,857) | |
| Number of Restricted Shares, Canceled | 0 | |
| Number of Restricted Shares, Non-vested at End of Period | 28,989 | |
Financial and Other Guarantees Financial and Other Guarantees (Details) $ in Thousands |
3 Months Ended |
|---|---|
|
Jun. 30, 2020
USD ($)
| |
| Product Warranty Liability [Line Items] | |
| Balance, March 31, 2017 | $ 7,381 |
| Warranties issued during the period | 2,234 |
| Settlement made during the period | (2,613) |
| Balance, June 30, 2017 | $ 7,002 |
Derivatives and Hedging Fair Value of Derivatives, Balance Sheet Location (Details) $ in Thousands, € in Millions, $ in Millions, $ in Millions |
3 Months Ended | ||||
|---|---|---|---|---|---|
|
Jun. 30, 2020
USD ($)
lb
|
Jun. 30, 2020
CAD ($)
|
Jun. 30, 2020
MXN ($)
|
Jun. 30, 2020
EUR (€)
|
Mar. 31, 2020
USD ($)
|
|
| Derivative [Line Items] | |||||
| Non-derivative Net Investment Hedge | $ 46,698 | ||||
| Prepaid & Other | |||||
| Derivative [Line Items] | |||||
| Asset derivatives | 451 | $ 124 | |||
| Liability derivatives | 0 | 0 | |||
| Accrued expenses and other | |||||
| Derivative [Line Items] | |||||
| Asset derivatives | 0 | 0 | |||
| Liability derivatives | $ 777 | $ 912 | |||
| Commodity swap contracts | |||||
| Derivative [Line Items] | |||||
| Derivative, notional amount, weight | lb | 536,400 | ||||
| Mexican peso | Foreign currency forward contracts | |||||
| Derivative [Line Items] | |||||
| Liability derivatives | $ 99.0 | ||||
| Canadian dollar | Foreign currency forward contracts | |||||
| Derivative [Line Items] | |||||
| Liability derivatives | $ 6.3 | ||||
| euro | Foreign currency forward contracts | |||||
| Derivative [Line Items] | |||||
| Derivative, notional amount | € | € 11.3 | ||||
Derivatives and Hedging Gain (Loss) on Derivatives, Income Statement Location (Details) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Foreign currency forward contracts | Selling, general, and administrative expense | ||
| Derivative Instruments, Gain (Loss) [Line Items] | ||
| Amount of gain (loss) recognized in income | $ (143) | $ (406) |
| Commodity swap contracts | Cost of revenues | ||
| Derivative Instruments, Gain (Loss) [Line Items] | ||
| Amount of gain (loss) recognized in income | $ 364 | $ (127) |
Fair Value Measurements Fair Value Hierarchy (Details) - USD ($) $ in Thousands |
3 Months Ended | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Mar. 31, 2020 |
Jun. 30, 2018 |
|||||||||
| Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] | ||||||||||||
| Debt and Equity Securities, Gain (Loss) | $ (309) | $ 1,758 | ||||||||||
| Assets: | ||||||||||||
| Investment Owned, at Cost | $ 4,955 | |||||||||||
| Liabilities: | ||||||||||||
| Contingent consideration obligations | 15,976 | $ 15,988 | ||||||||||
| Level 1 | ||||||||||||
| Assets: | ||||||||||||
| Cash and cash equivalents | 255,627 | 319,581 | ||||||||||
| Forward and swap contracts | [1] | 0 | 0 | |||||||||
| Equity Securities, FV-NI | [2] | 9,979 | 9,624 | |||||||||
| Investments | 2,550 | 2,507 | ||||||||||
| Liabilities: | ||||||||||||
| Forward and swap contracts | [1] | 0 | 0 | |||||||||
| Deferred compensation plans | [2] | 1,630 | 1,475 | |||||||||
| Long term debt | [3] | 0 | 0 | |||||||||
| Contingent consideration obligations | [4] | 0 | 0 | |||||||||
| Level 2 | ||||||||||||
| Assets: | ||||||||||||
| Cash and cash equivalents | 0 | 0 | ||||||||||
| Forward and swap contracts | [1] | 451 | 124 | |||||||||
| Equity Securities, FV-NI | [2] | 0 | ||||||||||
| Investments | 0 | 0 | ||||||||||
| Liabilities: | ||||||||||||
| Forward and swap contracts | [1] | 777 | 912 | |||||||||
| Deferred compensation plans | [2] | 0 | 0 | |||||||||
| Long term debt | [3] | 1,095,965 | 1,143,978 | |||||||||
| Contingent consideration obligations | [4] | 0 | 0 | |||||||||
| Level 3 | ||||||||||||
| Assets: | ||||||||||||
| Cash and cash equivalents | 0 | 0 | ||||||||||
| Forward and swap contracts | [1] | 0 | 0 | |||||||||
| Investments | 0 | |||||||||||
| Liabilities: | ||||||||||||
| Forward and swap contracts | [1] | 0 | 0 | |||||||||
| Deferred compensation plans | [2] | 0 | 0 | |||||||||
| Long term debt | [3] | 0 | 0 | |||||||||
| Contingent consideration obligations | [4] | 15,976 | 15,988 | |||||||||
| Carrying Value | ||||||||||||
| Assets: | ||||||||||||
| Cash and cash equivalents | 255,627 | 319,581 | ||||||||||
| Forward and swap contracts | [1] | 451 | 124 | |||||||||
| Equity Securities, FV-NI | [2] | 9,979 | 9,624 | |||||||||
| Investments | 2,550 | 2,507 | ||||||||||
| Liabilities: | ||||||||||||
| Forward and swap contracts | [1] | 777 | 912 | |||||||||
| Deferred compensation plans | [2] | 1,630 | 1,475 | |||||||||
| Long term debt | [3] | 1,057,156 | 1,150,521 | |||||||||
| Contingent consideration obligations | [4] | $ 15,976 | $ 15,988 | |||||||||
| ||||||||||||
Fair Value Measurements Contingent Consideration Rollforward (Details) - USD ($) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
Jun. 30, 2020 |
Mar. 31, 2020 |
|||
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||
| Contingent consideration | $ 15,976 | $ 15,988 | ||
| Additions | ||||
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||
| Change in contingent consideration | 111 | |||
| Payments | ||||
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||
| Change in contingent consideration | (21) | |||
| Foreign currency translation adjustment | ||||
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||
| Change in contingent consideration | (102) | |||
| Fair Value, Inputs, Level 3 [Member] | ||||
| Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items] | ||||
| Contingent consideration | [1] | $ 15,976 | 15,988 | |
| Fair value | $ 0 | |||
| ||||
Fair Value Measurements Available-for-sale securities (Details) - USD ($) $ in Thousands |
3 Months Ended | |
|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
|
| Debt Securities, Available-for-sale [Line Items] | ||
| Equity Securities, FV-NI, Gain (Loss) | $ 309 | $ (1,758) |
Reclassifications out of Accumulated Other Comprehensive Income Reclassification out of Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands |
3 Months Ended | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Jun. 30, 2020 |
Jun. 30, 2019 |
Mar. 31, 2020 |
Mar. 31, 2019 |
|||||||||||
| Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||||||||
| Accumulated Other Comprehensive Income (Loss), Net of Tax | $ (208,354) | $ (156,844) | $ (235,463) | $ (159,778) | ||||||||||
| Other Comprehensive Income (Loss), Net of Tax | 27,937 | 3,629 | ||||||||||||
| Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax | 828 | 695 | ||||||||||||
| Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent | (27,109) | (2,934) | ||||||||||||
| Accumulated Defined Benefit Plans Adjustment Attributable to Parent [Member] | ||||||||||||||
| Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||||||||
| Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax | 7,323 | [1] | 4,709 | [2] | 6,813 | [1] | 4,204 | [2] | ||||||
| Other Comprehensive Income (Loss), Net of Tax | (318) | [1] | (190) | [2] | ||||||||||
| Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax | 828 | [1] | 695 | [2] | ||||||||||
| Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent | 510 | [1] | 505 | [2] | ||||||||||
| Accumulated Foreign Currency Adjustment Attributable to Parent [Member] | ||||||||||||||
| Reclassification Adjustment out of Accumulated Other Comprehensive Income [Line Items] | ||||||||||||||
| Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax | [3] | (201,031) | (152,135) | $ (228,650) | $ (155,574) | |||||||||
| Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax | [3] | 27,619 | 3,439 | |||||||||||
| Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax | [3] | 0 | 0 | |||||||||||
| Other Comprehensive (Loss) Income, Net of Tax, Portion Attributable to Parent | [3] | $ (27,619) | $ (3,439) | |||||||||||
| ||||||||||||||
Loans Receivable (Details) € in Thousands, $ in Thousands |
9 Months Ended | 12 Months Ended | |||||||
|---|---|---|---|---|---|---|---|---|---|
Dec. 31, 2019 |
Mar. 31, 2017
EUR (€)
|
Jun. 30, 2020
USD ($)
|
Jun. 30, 2020
EUR (€)
|
Mar. 31, 2020
USD ($)
|
Mar. 31, 2020
EUR (€)
|
Oct. 31, 2019
EUR (€)
|
Jun. 30, 2019 |
Jun. 30, 2018
USD ($)
|
|
| Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||||||
| Investments | $ 4,955 | ||||||||
| Line of Credit Provide | $ 11,000 | ||||||||
| Financing Receivable, after Allowance for Credit Loss | $ 7,316 | $ 7,084 | |||||||
| Interest Rate Period | 4 years | 15 years | |||||||
| Years 1-4, 4% Int Rate [Member] | |||||||||
| Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||||||
| Interest rate on loan receivable | 4.00% | 4.00% | |||||||
| Loan Rate 4% [Member] [Domain] | |||||||||
| Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||||||
| Interest rate on loan receivable | 4.00% | ||||||||
| Years 5-15, 12% Int Rate [Member] | |||||||||
| Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||||||
| Interest rate on loan receivable | 12.00% | ||||||||
| Years 5-6,8% Int Rate [Member] [Member] | |||||||||
| Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||||||
| Interest rate on loan receivable | 8.00% | ||||||||
| Dutch Linen Loan [Domain] | |||||||||
| Accounts, Notes, Loans and Financing Receivable [Line Items] | |||||||||
| Other Receivables | € | € 7,300 | ||||||||
| Financing Receivable, after Allowance for Credit Loss | $ 8,210 | € 7,300 | $ 8,072 | € 7,300 | |||||
| Loan Agreement Max Borrowing Amount Dutch Linen Sale | € | € 15,000 | ||||||||
Restructuring (Details) $ in Thousands |
3 Months Ended | |||
|---|---|---|---|---|
|
Jun. 30, 2020
USD ($)
plan
|
Jun. 30, 2019
USD ($)
|
|||
| Restructuring and Related Cost, Expected Number of Positions Eliminated | plan | 200 | |||
| Restructuring expense incurred since Plan inception | $ 44,017 | |||
| Restructuring Costs | 166 | $ 1,389 | ||
| Restructuring Charges | [1] | 166 | $ 2,307 | |
| Operating Expense [Member] | ||||
| Restructuring Charges | 31,826 | |||
| Cost of Goods and Service Benchmark [Member] | ||||
| Restructuring Charges | 12,191 | |||
| Healthcare Products [Member] [Member] | ||||
| Restructuring Charges | 33,819 | |||
| Applied Sterilization Technologies [Member] | ||||
| Restructuring Charges | 7,798 | |||
| Life Science Member [Member] | ||||
| Restructuring Charges | 668 | |||
| Corporate, Non-Segment [Member] | ||||
| Restructuring Charges | $ 1,732 | |||
| ||||